These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 6495946)

  • 1. [Various methods of overcoming secondary resistance to treatment developing in relation to adaptation to psychotropic drugs during long-term treatment (clinico-experimental study)].
    Avrutskiĭ GIa; Allikmets LKh; Neduva AA; Zharkovskiĭ AM; Beliakov AV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(8):1213-20. PubMed ID: 6495946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adaptation to neuroleptic preparations and several ways of combatting it (experimental study)].
    Neduva AA; Zharkovskiĭ AM; Matvienko OA; Beliakov AV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(8):1226-31. PubMed ID: 4050238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
    Zharkovskiĭ AM; Matvienko OA; Nurk AM
    Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
    Schweitzer JW; Schwartz R; Friedhoff AJ
    Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):21-30. PubMed ID: 7146618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of varying the dose of haloperidol during its prolonged administration on the development of tolerance and hypersensitivity in dopamine receptors].
    Zharkovskiĭ AM; Beliakov AV
    Farmakol Toksikol; 1983; 46(5):22-4. PubMed ID: 6628655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hostile, suspicious patients. Trifluoperazine versus haloperidol.
    O'Brien CP; DiGiacomo JN; Webb W
    Dis Nerv Syst; 1974 Feb; 35(2):75-8. PubMed ID: 17894044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing time-dependent tolerance of catalepsy by repetitive administration of haloperidol in mice.
    Viyoch J; Ohdo S; Yukawa E; Higuchi S
    J Pharmacol Exp Ther; 2001 Sep; 298(3):964-9. PubMed ID: 11504791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polypharmacy in psychiatry: a multi-state comparison of psychotropic drug combinations.
    Sheppard C; Beyel V; Fracchia J; Merlis S
    Dis Nerv Syst; 1974 Apr; 35(4):183-9. PubMed ID: 17894114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats.
    Agovic MS; Yablonsky-Alter E; Lidsky TI; Banerjee SP
    Eur J Pharmacol; 2008 Jun; 587(1-3):181-6. PubMed ID: 18457824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
    Davidkova G; Zhou LW; Morabito M; Zhang SP; Weiss B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1187-96. PubMed ID: 9618422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific involvement of striatal D1 and D2 dopamine receptors in the neuroleptic catalepsy in rats.
    Wardas J; Pietraszek M; Ossowska K; Wolfarth S
    Pol J Pharmacol; 1995; 47(4):349-53. PubMed ID: 8616516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic haloperidol does not increase specific dopamine receptor binding in rat frontal cortex.
    Meller E; Bohmaker K; Rosengarten H; Friedhoff AJ
    Res Commun Chem Pathol Pharmacol; 1982 Sep; 37(3):323-32. PubMed ID: 7178646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Complex use of phenazepam, lithium and haloperidol in the treatment of several forms of schizophrenia].
    Mosketi KV; Mokhovikov AN; Aksent'ev SB; Goĭkhberg IG; Kryzhanovskiĭ GN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(4):589-96. PubMed ID: 6730829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of dopamine system in regulation of Na+,K+-ATPase in the striatum upon activation of opioid receptors by morphine.
    Wu ZQ; Chen J; Chi ZQ; Liu JG
    Mol Pharmacol; 2007 Feb; 71(2):519-30. PubMed ID: 17068092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aging and the regulation of striatal dopaminergic mechanisms in mice.
    Randall PK; Severson JA; Finch CE
    J Pharmacol Exp Ther; 1981 Dec; 219(3):695-700. PubMed ID: 7197719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia.
    Volz HP; Möller HJ; Gerebtzoff A; Bischoff S
    Eur Arch Psychiatry Clin Neurosci; 2002 Apr; 252(2):76-80. PubMed ID: 12111340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual differences in the response of dopamine receptor number to chronic haloperidol treatment.
    Bannet J; Belmaker RH; Ebstein RP
    Biol Psychiatry; 1981 Nov; 16(11):1059-65. PubMed ID: 7349620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of several psychotic states with the combination of valproic acid with diazepam].
    Bourguignon A; Monfort JC; de Medeiros P; Cadet B; Chaneac D
    Ann Med Psychol (Paris); 1984 Nov; 142(9):1214-8. PubMed ID: 6442960
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.
    Yanahashi S; Hashimoto K; Hattori K; Yuasa S; Iyo M
    Brain Res; 2004 Jun; 1011(1):84-93. PubMed ID: 15140647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.